How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.

Item

http://www.wikidata.org/entity/Q53098336

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

How to determine bortezomib-ba ...... s CBd, an observational study.

@en

How to determine bortezomib-ba ...... s CBd, an observational study.

@nl

type

Item

label

How to determine bortezomib-ba ...... s CBd, an observational study.

@en

How to determine bortezomib-ba ...... s CBd, an observational study.

@nl

prefLabel

How to determine bortezomib-ba ...... s CBd, an observational study.

@en

How to determine bortezomib-ba ...... s CBd, an observational study.

@nl

P1476

How to determine bortezomib-ba ...... us CBd, an observational study

@en

P2093

Bin-Tao Huang

http://www.w3.org/2001/XMLSchema#string

Bing-Sheng Li

http://www.w3.org/2001/XMLSchema#string

Rui-Lin Chen

http://www.w3.org/2001/XMLSchema#string

Wei-Hong Zhao

http://www.w3.org/2001/XMLSchema#string

Yan Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

International staging system for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.

High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

P2888

s00432-013-1570-6

P304

303-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-013-1570-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

Qing-Chun Zeng

P577

2013-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259322103

http://www.w3.org/2001/XMLSchema#string

P698

24337419

http://www.w3.org/2001/XMLSchema#string